



PolyNovo Limited
ABN 96 083 866 862

2/320 Lorimer Street
Port Melbourne
VIC Australia 3207

P +61 (0) 3 8681 4050
F +61 (0) 3 8681 4099

10 November 2022

ASX Announcement

Chairman's address at Bell Potter Healthcare Conference

The Chairman David Williams is speaking at the Bell Potter Healthcare Conference at 9am this morning about the near and medium term prospects for PolyNovo.

His summary address is attached and will be shared with conference participants.

This announcement has been authorised by PolyNovo Company Secretary Jan-Marcel Gielen.

About PolyNovo®

PolyNovo is a disruptive medical device company, focused on Advanced Wound Care. PolyNovo is an Australian based medical device company that designs, develops, and manufactures dermal regeneration solutions (NovoSorb BTM) using its patented NovoSorb biodegradable polymer technology. Our development program covers Breast Sling, Hernia, and Orthopaedic applications. For further information and market presentations see www.polynovo.com

About NovoSorb® BTM

NovoSorb® BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery or burn. NovoSorb® is a novel range of bio-resorbable polymers that can be produced in many formats including, film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.

David Williams - Chairman's address

Bell Potter Healthcare Conference



Update:

- Q1 record BTM sales AUD 12.5m up 73.3% on STLY
- First ever AUD 5m sales month in September
- October trading: Not lumpy
- Hong Kong: Two more
- Launched in Canada two weeks ago
- Launching in India today
- Strengthening head office organization structure

Five Growth Platforms for the year ahead

- Sales team Expansion: U.S. 36 to 56, UKI 3 to 6, ANZ 5 to 8, India 0 to 2 to 7 to 17, Canada 0 to 7. Supported by Masterclasses for surgeons in India and Hong Kong.
- Geographic Expansion: India, Hong Kong, Canada with revenue and sales. Japan and China exploratory talks.
- Indication Expansion: (skin cancer, vascular wounds / limb salvage, free flaps and spina bifida)
- Product Expansion:
 - FDA 510(k) for NovoSorb MTX
 - David McQuillan (9 in R&D)
- Channel Expansion (Considering plastics, outpatients, podiatry).
- New alliances and corporate actions